Business Wire

CA-USERTESTING,-INC.

24.3.2021 14:02:16 CET | Business Wire | Press release

Share
UserTesting’s Eighth Annual CX Survey Reveals That Customer Empathy Is No Longer Optional

UserTesting , a leading provider of on-demand human insights , today released new data identifying how the pandemic has put customer experience (CX) and empathy center stage. Findings show that businesses are in one of two categories, those doubling down on CX and those scaling back on it, and that customer feedback collection is on the rise, with 72 percent of organizations stating that they plan to increase their investments in 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005313/en/

The vast majority, 71 percent , noted that they’re either in-process or have completed their digital transformation. This is a sharp increase from 2019 survey results, in which only 56 percent said they were that far along in their journey. This indicates that the pandemic has helped to motivate teams to dedicate more time and resources to digital transformation to improve overall CX.

The 2021 CX Industry Report uncovered three key trends influencing customer experience today:

  • Feedback has gone remote
    The remote-centric business environment brought about by the pandemic is, for many, here to stay. A remote-first approach to customer feedback is a new strategy that many companies will continue to embrace into the new normal, and for good reason. The survey revealed that moving to online user research can cut costs by an average of 40 percent . The impact on a company’s bottom line is also significant. Moving to online user research was found to increase revenue by about 40 percent . Many survey respondents noted that the pandemic will permanently reduce the amount of in-person research they do moving forward.
  • The pandemic has put the focus on CX
    Although consumers’ interactions with brands have changed, expectations have never been higher. The survey found that companies acknowledge an increase in the use of customer feedback, which drove more investments into customer feedback and user research. Both trends are likely to continue. Despite the efforts to improve CX, many survey respondents noted their companies are still in the early stages of establishing their CX practices with 60 percent admitting that their organization doesn’t have a formal CX strategy in place or only reacts to issues as they happen.
  • Teams are doing more with less
    Time and resources were significantly impacted by the pandemic which, in many cases, meant more work with fewer resources. Nearly 70 percent of those surveyed reported reductions in spending or workforce resources due to business changes caused by the pandemic. Fewer resources impacted nearly half of those surveyed with 53 percent reporting an increase in workload. The pandemic also required many companies to quickly pivot their product or service offerings. Forty-six percent of respondents reported a change to their product roadmap due to the pandemic.

“We have been through a year unlike any other where organizations have had to adapt to changing customer needs. The past year has shown that organizations must prioritize customer understanding and empathy to build long term customer loyalty,” said Janelle Estes, Chief Insights Officer at UserTesting. “The takeaway for every size organization should be that talking with and listening to your customers cannot take place only during times of crisis but should be part of regular business practices.”

To access the full UserTesting 2021 CX Industry Report, click here .

Methodology and survey results

In this eighth annual Customer Experience Industry Survey, we asked over 4,700 professionals from around the world across a wide variety of industries how their organizations are approaching customer experience and conducting CX research.

About UserTesting

UserTesting enables every organization to deliver the best customer experience powered by human insight. With UserTesting’s on-demand Human Insight Platform , companies across industries make accurate customer-first decisions at every level, at the speed business demands. With UserTesting, product teams, marketers, digital, and customer experience executives, designers and UX researchers confidently and quickly create the right experiences for all target audiences, increasing brand loyalty and revenue. UserTesting customers include more than half of the world’s top brands. UserTesting is headquartered in San Francisco, CA. To learn more, visit www.usertesting.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release

New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p

Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release

By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release

Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release

Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye